| SKU:K1323 | M. Wt:447.88 | ||
| Formula:C23H23ClFNO5 | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:697761-98-1 | Synonyms:N/A | ||
| Chemical NameN/A | |||
| 供货周期： | 一周 |
| 品牌： | |
| 规格： | 2mg |
| 货号： | K1323 |
| CAS号： | 697761-98-1 |
| SKU:K1323 | M. Wt:447.88 | ||
| Formula:C23H23ClFNO5 | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:697761-98-1 | Synonyms:N/A | ||
| Chemical NameN/A | |||
| Description | Elvitegravir (GS-9137) | |||||
|---|---|---|---|---|---|---|
| Targets | HIV-1 IIIB | HIV-2 EHO | HIV-2 ROD | |||
| IC50 | 0.7 nM | 2.8 nM | 1.4 nM | |||
| In vitro | Elvitegravir (EVG, JTK-303/GS-9137) can inhibit HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM. Elvitegravir is predominantly metabolized via cytochrome P450 (CYP)3A4, along with minor pathways including glucuronidation via UGT1A1/3 and oxidative metabolism. Elvitegravir (EVG, JTK-303, GS-9137) currently being developed for the treatment of HIV-1 infection. Elvitegravir was more potent than raltegravir,a newly approved anti-AIDS drug. Elvitegravir can inhibit clinical HIV-2 isolates with IC50 of 0.7 nM while raltegravir inhibits those HIV-2 isolates with IC50 of 2.4 nM. Neither elvitegravir nor raltegravir could block disintegration. Elvitegravir (EVG) blocks the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. Elvitegravir can inhibit the replication of HIV-1, including various subtypes and multiple-drug-resistant clinical isolates, and HIV-2 strains with a 50% effective concentration in the subnanomolar to nanomolar range. Clade-specific HIV-1 integrase polymorphisms do not reduce elvitegravir phenotypic susceptibility. | |||||
| In vivo | Elvitegravir pharmacokinetic GMR was 6-7% higher following elvitegravir/r plus etravirine dosing versus elvitegravir/r. The coadministration of elvitegravir with the protease inhibitor ritonavir (a substantial CYP3A4 inhibitor) results in significantly enhanced bioavailability and a longer half-life than with elvitegravir alone, allowing for the once-daily dosing of elvitegravir. | |||||
| Clinical Trials | N/A | |||||
| Features | N/A | |||||
相关产品
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清（无支原体）
超级新生牛血清（无支原体）
优级胎牛血清（无支原体）
特级新生牛血清（无噬菌体低内毒素）
工商信息
信息已认证
联系方式
详细地址
关注
拨打电话
留言咨询
